Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma That Aim to Achieve and Maintain Measurable Residual Disease (MRD)-Negativity in Community Oncology Settings
All4Cure
Summary
All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achieve and maintain MRD negativity. This is a longitudinal retrospective study that will collect data from three separate cohorts of patients with newly diagnosed multiple myeloma (NDMM). The cohorts classify patients based on whether care is delivered under an intention to adhere to an MRD-targeted clinical pathway, and if so, whether the implementation of that clinical pathway occurs through participation in the All4Cure platform vs. through written documentation. The three cohorts are labeled: Platform, Documentation, and Off-Pathway.
Description
The study will employ two implementations of an MRD-targeted pathway one that disseminates pathway guidance through written documentation, and another that leverages the All4Cure platform to support pathway adherence through direct engagement of other experts, and through integration of elements of the MRD-targeted pathway into the structured components of the platform. The study also includes a comparator cohort of patients not being treated according to the clinical pathway. Analysis under the primary objective will evaluate outcomes between patients being treated following written pathway d…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- Not specified
Inclusion Criteria: * Diagnosis of multiple myeloma * Diagnosis must occur on or after the formal launch of the MRD-targeted clinical pathway in the Exigent network * Diagnosis must be indicated by the presence of any of the following diagnostic codes for multiple myeloma: \[C90.00\] * Diagnosis must be confirmed on human review of the medical record * Age ≥ 18 years at qualifying diagnosis. * Patient has continued to receive care at a QCCA/Exigent Research practice for at least 90 days after the index date. Patients in the Documentation Cohort must meet the following additional inclu…
Interventions
- OtherMultiple Myeloma Pathway
Use and adherence to a multiple myeloma pathway.
- OtherAll4Cure Platform
Participant in the All4Cure platform.
- OtherDocumentation Pathway
Use of multiple myeloma pathway through written documentation.
Location
- All4CureSeattle, Washington